Full Press Release Details
JYONG BIOTECH LIMITED
UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE
(in thousand US Dollars, except share and per share data)
| As of December 31, 2024 | As of June 30, 2025 | |||||||
| Audited | Unaudited | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | $ | 98 | $ | 132 | ||||
| Restricted cash | 3 | 3 | ||||||
| Short-term investments | - | 16,875 | ||||||
| Prepayments and other current assets | 105 | 153 | ||||||
| Total current assets | 206 | 17,163 | ||||||
| Property and equipment, net | 3,049 | 3,358 | ||||||
| Operating right-of-use assets | 137 | 94 | ||||||
| Deferred offering costs | 934 | - | ||||||
| Restricted asset | 2,034 | 2,049 | ||||||
| Loan receivable from shareholder | - | 15,000 | ||||||
| Other non-current assets | 6 | 7 | ||||||
| Total non-current assets | 6,160 | 20,508 | ||||||
| TOTAL ASSETS | $ | 6,366 | $ | 37,671 | ||||
| LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||
| Current liabilities | ||||||||
| Short-term bank loans | $ | 7,225 | $ | 22,436 | ||||
| Notes and accounts payable | 3 | 3 | ||||||
| Accrued expenses | 1,203 | 991 | ||||||
| Accrued expenses due to related parties | 147 | 219 | ||||||
| Current portion of long-term bank loans | 57 | 349 | ||||||
| Operating lease liabilities due to related parties-current | 159 | 131 | ||||||
| Other current liabilities | 3,292 | 3,366 | ||||||
| Other current liabilities due to related parties | 41 | 59 | ||||||
| Total current liabilities | 12,127 | 27,554 | ||||||
| Long-term loan from related parties | 5,515 | 7,195 | ||||||
| Long-term loan from third parties | 3,131 | 3,131 | ||||||
| Long-term bank loans, net of current portion | 2,032 | 1,945 | ||||||
| Operating lease liabilities due to related parties - non-current | 16 | 7 | ||||||
| Other non-current liabilities | 58 | 58 | ||||||
| Other non-current liabilities due to related parties | 628 | 628 | ||||||
| Guarantee liabilities | 19,378 | 19,625 | ||||||
| Total non-current liabilities | 30,758 | 32,589 | ||||||
| TOTAL LIABILITIES | 42,885 | 60,143 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders' deficit | ||||||||
| Ordinary shares, $0.00001 par value; 5,000,000 thousand shares authorized; 73,361 thousand and 76,028 thousand shares issued and outstanding as of December 31, 2024 and June 30, 2025, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 11,805 | 28,263 | ||||||
| Treasury shares, 1,794 thousand shares as of December 31, 2024 and June 30, 2025 | (16,366 | ) | (16,366 | ) | ||||
| Accumulated deficit | (33,080 | ) | (34,332 | ) | ||||
| Accumulated other comprehensive income (loss) | 1,121 | (38 | ) | |||||
| Total shareholders' deficit | (36,519 | ) | (22,472 | ) | ||||
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | $ | 6,366 | $ | 37,671 |
JYONG BIOTECH LIMITED
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(in thousand US Dollars, except share data in
thousands and per share data)
| For the six months ended June 30, | ||||||||
| 2024 | 2025 | |||||||
| Unaudited | Unaudited | |||||||
| Operating expenses | ||||||||
| Research and development | $ | (499 | ) | $ | (367 | ) | ||
| Selling and marketing | (21 | ) | (20 | ) | ||||
| General and administrative | (431 | ) | (429 | ) | ||||
| Total operating expenses | (951 | ) | (816 | ) | ||||
| Loss from operations | (951 | ) | (816 | ) | ||||
| Other incomes (expenses): | ||||||||
| Interest income | 6 | 24 | ||||||
| Interest expenses | (448 | ) | (417 | ) | ||||
| Other gains (losses), net | 67 | (43 | ) | |||||
| Total other expenses, net | (375 | ) | (436 | ) | ||||
| Loss before income tax | (1,326 | ) | (1,252 | ) | ||||
| Income tax expense | - | - | ||||||
| Net loss | (1,326 | ) | (1,252 | ) | ||||
| Other comprehensive income (loss) | ||||||||
| Foreign currency translation adjustments, net of nil tax | 473 | (1,163 | ) | |||||
| Unrealized gain on short term investments, net of nil tax | - | 4 | ||||||
| Total other comprehensive income (loss) | 473 | (1,159 | ) | |||||
| Total comprehensive loss | $ | (853 | ) | $ | (2,411 | ) | ||
| Net loss per share: | ||||||||
| Basic and Diluted | $ | (0.02 | ) | $ | (0.02 | ) | ||
| Weighted average shares outstanding (in thousands): | ||||||||
| Basic and Diluted | 71,567 | 71,758 |